english questionnaire - World Health Organization
english questionnaire - World Health Organization
english questionnaire - World Health Organization
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4. Goldberg, A.I., et al. (1998). Physician assessments of patient compliance with medical<br />
treatment, Soc. Sci. Med., 47(11): 1873–1876.<br />
5. Playle, J.F. and Keeley, P. (1998). Non-compliance and professional power, J. Adv. Nurs. 27: 304–<br />
311.<br />
6. Bredenberg, S., et al. (2003). In vitro and in vivo evaluation of a new sublingual tablet system for<br />
rapid oramucosal absorption using fentanyl citrate as the active substance, Eur. J. Pharm.<br />
Biopharm., 20: 327–334.<br />
7. de Vries, M.E., et al. (1991). Developments in buccal drug delivery, Cri. Rev. Ther. Drug Carr. Sys.<br />
8: 271–303.<br />
8. Rathbone, M.J. and Hadgraft, J. (1991). Absorption of drugs from the human oral cavity, Int. J.<br />
Pharm., 74: 9–24.<br />
9. Squier, C.A. (1991). The permeability of oral mucosa, Cri. Rev. Oral Biol., Med. 2: 13–32.<br />
10. Lee, H.J. (2002). Protein drug oral delivery: The recent progress, Arch. Pharm. Res., 25: 572–84.<br />
11. Pillay, V. and Fassihi, R. (1999a). In vitro release modulation from crosslinked pellets for sitespecific<br />
drug delivery to the gastrointestinal tract: I. Comparison of pH-responsive drug release<br />
and associated kinetics, J. Contr. Rel., 59: 229–242.<br />
(Approximately 400 words)<br />
7.* Explain which new and innovative approaches and mechanisms to supporting<br />
financing and coordination of R&D this project would demonstrate?<br />
(This is a very important part to be filled. The idea of these demonstrations projects is<br />
“to address identified gaps that disproportionately affect developing countries,<br />
particularly the poor, and for which immediate action can be taken” (WHA66.22). 66 th<br />
WHA considered these demonstration projects as part of the efforts to “take forward<br />
action in relation to monitoring, coordination and financing for health research and<br />
development”. The assembly decided to identify such projects that: “(a) address<br />
identified research and development gaps related to discovery, development and/or<br />
delivery, including promising product pipelines, for diseases that disproportionally<br />
affect developing countries, particularly the poor, and for which immediate action can<br />
be taken; (b) utilize collaborative approaches, including open-knowledge approaches,<br />
for research and development coordination; (c) promote the de-linkage of the cost of<br />
research and development from product price; and (d) propose and foster financing<br />
mechanisms including innovative, sustainable and pooled funding; (2) The<br />
demonstration projects should provide evidence for long-term sustainable solutions.”)<br />
Address research and development gaps:<br />
This project aims to design and develop an ultra-fast disintegrating WaferMat formulation that<br />
utilizes and alternative platform with several differentiating features for optimal buccal<br />
administration of antiretrovirals in paediatric HIV. The proposed WaferMat formulation is designed<br />
for oral antiretroviral drug delivery directly into the systemic circulation via the buccal mucosa<br />
(inside of the cheek) and avoids the GIT issues as highlighted earlier. The WaferMat is envisaged to<br />
be a small (8x3mm 2 ) disc-shaped formulation that can be placed on the inside of the cheek where it<br />
dissolves in less than 3 seconds. There is no risk of accidentally swallowing the WaferMat because<br />
it rapidly adheres to the buccal mucosa while dissolving. The antiretroviral drug is released and<br />
absorption occurs through the inside of the cheek and reaches the systemic circulation without<br />
drug been swallowed. This strategy is crucial since antiretroviral drugs have poor solubility and<br />
permeability when delivered orally to the GIT. There are a few orodispersible adult dosage forms<br />
4